Background: Clostridium difficile colitis is a nosocomial infection that can present as minor, readily treated symptoms or as fulminant colitis leading to death. Risk factors for C. difficile colitis have been defined, and certain populations of hospitalized patients appear to be particularly susceptible. However, most information on C. difficile colitis is from large tertiary-care medical centers. Whether the community hospital experience is similar to that of large referral centers is unknown.

Methods: We abstracted all cases of C. difficile colitis (ICD-9-CM 008.45) for 2003-2005 from a state database and divided the hospitals into academic and nonacademic centers. Cases were stratified according to whether the colitis was listed as the primary presenting diagnosis or a secondary diagnosis. Demographic information, associated diagnoses, length of stay, and deaths were analyzed.

Results: The incidence of C. difficile colitis increased from 2003 to 2005, and the majority of cases occurred at nonacademic centers. Patients in nonacademic centers more frequently had C. difficile colitis as the primary diagnosis, had a shorter length of stay, were older, and were more frequently women. The mortality rate was higher for secondary (8.5%) than for primary (2.6%; p < 0.05) C. difficile colitis, but there was no difference between academic and nonacademic centers.

Conclusions: The incidence of C. difficile colitis is increasing in this statewide database. Compared with academic medical centers, nonacademic centers deal with a higher rate of primary C. difficile colitis that is associated with a lower mortality rate and shorter stay than secondary colitis.

Download full-text PDF

Source
http://dx.doi.org/10.1089/sur.2009.033DOI Listing

Publication Analysis

Top Keywords

difficile colitis
28
nonacademic centers
12
colitis
9
clostridium difficile
8
medical centers
8
length stay
8
difficile
7
centers
6
statewide experience
4
experience clostridium
4

Similar Publications

Background: Fecal microbiota, live-jslm (RBL; REBYOTA®), is the first single-dose, broad consortia, microbiota-based live biotherapeutic approved by the US Food and Drug Administration to prevent recurrent Clostridioides difficile infection (rCDI) in adults following standard-of-care antimicrobials. Inflammatory bowel disease (IBD) is a common risk factor for rCDI, yet patients with IBD are often excluded from prospective trials. This subgroup analysis of PUNCH CD3-OLS (NCT03931941) evaluated the safety and efficacy of RBL in participants with rCDI and IBD.

View Article and Find Full Text PDF

infection (CDI), characterized by colitis and diarrhea, afflicts approximately half a million people in the USA every year, burdening both individuals and the healthcare system. 630Δ is an erythromycin-sensitive variant of the clinical isolate 630 and is commonly used in the research community due to its genetic tractability. 630Δ possesses a point mutation in , an autoregulated transcriptional repressor that regulates oxidative stress resistance genes.

View Article and Find Full Text PDF

Enteral administration of vancomycin is the standard treatment for () colitis and is presumed to have no systemic absorption. In critically ill patients, however, especially with multi-organ failure, enteral absorption of vancomycin is unpredictable and can cause severe toxicity if it remains unrecognized. We therefore report a case of systemic absorption of enteric vancomycin in a patient with severe colitis.

View Article and Find Full Text PDF

Clostridioides difficile infection and recurrence in cancer patients (CIRCA): a multicentre, international study.

Int J Infect Dis

January 2025

Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC, Australia; Department of Infectious Diseases and National Center for Infection, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, VIC, Australia.

Objectives: We aimed to describe the characteristics of Clostridioides difficile infection (CDI) in cancer patients, analysing risk factors for 90-day recurrence and attributable mortality.

Methods: Retrospective analysis on all CDI episodes from 2020 to 2022 in three Australian hospitals and one Spanish hospital. Logistic regression analyses were performed.

View Article and Find Full Text PDF

Analysis of risk factors of infection in patients with inflammatory bowel disease.

Prz Gastroenterol

September 2024

Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Unit, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland.

Introduction: infection (CDI) is one of the most important challenges in contemporary gastroenterology. However, data from CDI studies are sometimes contradictory.

Aim: To analyse the risk factors for CDI in patients with inflammatory bowel disease (IBD).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!